Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, placebo-controlled, ascending single dose safety,
tolerability, and pharmacokinetic study of orally administered EDP-322. This study was
conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in
target patient populations.